Journal article
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab
P Jain, GM Nogueras González, R Kanagal-Shamanna, U Rozovski, N Sarwari, C Tam, WG Wierda, PA Thompson, N Jain, R Luthra, A Quesada, G Sanchez-Petitto, A Ferrajoli, J Burger, H Kantarjian, J Cortes, S O'Brien, MJ Keating, Z Estrov
British Journal of Haematology | WILEY | Published : 2018
DOI: 10.1111/bjh.15018
Abstract
The degree of somatic hypermutation, determined as percent deviation of immunoglobulin heavy chain gene variable region sequence from the germline (IGHV%), is an important prognostic factor in chronic lymphocytic leukaemia (CLL). Currently, a cut-off of 2% deviation or 98% sequence identity to germline in IGHV sequence is routinely used to dichotomize CLL patients into mutated and unmutated groups. Because dissimilar IGHV% cut-offs of 1–5% were identified in different studies, we wondered whether no cut-off should be applied and IGHV% treated as a continuous variable. We analysed the significance of IGHV% in 203 CLL patients enrolled on the original frontline fludarabine, cyclophosphamide an..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This study was supported in part by the NIH/NCI award number P30CA016672 and by NCI award number P01CA049639. We thank Chalaire Dawn from scientific publications department of MDACC, for editing the manuscript.